Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
32.7M
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
14.8M
-
Shares change
-
+226K
-
Total reported value, excl. options
-
$103M
-
Value change
-
+$1.48M
-
Put/Call ratio
-
0.08
-
Number of buys
-
21
-
Number of sells
-
-23
-
Price
-
$6.97
Significant Holders of NeuroPace Inc - Common Stock, $0.001 par value per share (NPCE) as of Q3 2024
60 filings reported holding NPCE - NeuroPace Inc - Common Stock, $0.001 par value per share as of Q3 2024.
NeuroPace Inc - Common Stock, $0.001 par value per share (NPCE) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.8M shares
of 32.7M outstanding shares and own 45.28% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (3.41M shares), MORGAN STANLEY (2.49M shares), Soleus Capital Management, L.P. (2.43M shares), Kent Lake PR LLC (1.25M shares), VANGUARD GROUP INC (995K shares), MILLENNIUM MANAGEMENT LLC (740K shares), BlackRock, Inc. (705K shares), Nantahala Capital Management, LLC (608K shares), ARMISTICE CAPITAL, LLC (480K shares), and DEUTSCHE BANK AG\ (412K shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.